Next-Generation Nutraceuticals

Content

• Executive Summary
  • Food and pharmaceutical disease prevention
  • Functional food and drinks
  • Technologies for nutrigenomics
  • The regulatory landscape
  • Strategies of leading ingredient, food, drinks and pharma companies
  • Future challenges and opportunities
• Chapter 1 Food and pharmaceutical disease prevention
  • Summary
  • Introduction
  • The changing approach to the health burden
  • New technologies
  • Key convergent markets
  • Obesity
  • Epidemiology
  • Sales
  • Cardiovascular disease
  • Epidemiology
  • Sales
  • Diabetes
  • Epidemiology
  • Sales
  • Bone health
  • Epidemiology
  • Sales
  • Conclusions
• Chapter 2 Functional food and drinks
  • Summary
  • Introduction
  • Functional food and drinks
  • Functional ingredients
  • Scientific evidence to support the health benefits of functional ingredients
  • Proving efficacy: pharma vs. food
  • Growth areas and product trends in the functional foods market
  • Heart health
  • Digestive health - Probiotics
  • Innovative ingredients aligning with pharma
  • Personalized nutrition
  • Conclusions
• Chapter 3 Technologies for nutrigenomics
  • Summary
  • Introduction
  • Biomic technologies in the pharma industry
  • Pharma technologies in the food industry
  • Genomics
  • Genomics in personalized nutrition
  • Case study: Sciona Inc
  • Transcriptomics
  • Transcriptomics in the food industry
  • Case study: WellGen Inc.
  • Proteomics
  • Metabolomics
  • Case study: the INTERMAP study
  • Challenges to metabolomics in nutrition research
  • Growth and interest in metabolomics
  • Systems Biology
  • Nanotechnology delivering new ingredients
  • Conclusions
• Chapter 4 The regulatory landscape
  • Summary
  • Introduction
  • Regulation of health claims for functional foods
  • Japan
  • United States
  • Health claims
  • Structure/function claims
  • Criticism of the FDA's approach
  • Europe
  • Opportunities and threats of functional food regulation
  • The future of functional food regulation
  • Regulation of personalized dietary advice
  • Conclusions
• Chapter 5 Strategies of leading ingredient, food, drinks and pharma companies
  • Summary
  • Introduction
  • Ingredient manufacturers
  • DSM
  • BASF
  • Chr. Hansen
  • Products
  • Research
  • Opportunities for the ingredients industry
  • Food and drinks manufacturers
  • Nestl
  • Nestl's products
  • Research
  • The future for Nestl
  • Unilever
  • Unilever's products
  • Research
  • The future for Unilever
  • Ajinomoto
  • Research and the future for Ajinomoto
  • Danone
  • The future for Danone
  • Coca-Cola
  • Other food and drinks manufacturers
  • Pharma companies
  • Future trends for the food and pharma industries
  • Agribusiness
  • vi Alliances
  • Food-pharma alliances
  • Alliances with new technology companies
  • Alliances for nutrigenomic research
  • Conclusions
• Chapter 6 Future challenges and opportunities
  • Summary
  • Introduction
  • Opportunities and market drivers
  • Consumer demand
  • Incentives
  • Opportunities in developing markets
  • New product development opportunities
  • Marketing
  • Challenges
  • Scientific challenges
  • Furthering basic and applied research
  • Clinical testing of nutraceuticals
  • Defining health
  • Ethical, legal and societal concerns
  • Ethical concerns
  • Societal concerns
  • Privacy and human rights
  • Research practices in nutrigenomics
  • The regulatory framework
  • Conclusions
• Chapter 7 Appendix
  • Bibliography
  • Index
  • Footnotes
• List of Figures
  • Figure 1.1: Drivers of change in the food and pharma industries
  • Figure 1.2: Examples of food and pharma approaches to heart disease
  • Figure 1.3: A functional food pyramid
  • Figure 1.4: The role of food and pharmaceuticals in the healthcare continuum
  • Figure 1.5: Examples of obesity drugs in development
  • Figure 1.6: Global deaths from cardiovascular disease
  • Figure 1.7: Drugs in clinical development for CV disorders
  • Figure 2.8: Top US consumer health concerns, 2005
  • Figure 2.9: Nutrigen IQ3 Yogurt Drink
  • Figure 2.10: Right Direction Cookies
  • Figure 2.11: DanaCol with Omega-3 & Plant Sterols Dairy Drink
  • Figure 2.12: Calpis Aqua Nyusankin
  • Figure 2.13: Calpis Interbalance L-92 Lactic Acid Bacteria Drink
  • Figure 3.14: The 'omics technologies: definitions
  • Figure 3.15: The 'omics technologies
  • Figure 3.16: The Cellf??Assessment Kit from Sciona
  • Figure 3.17: Pro-inflammatory metabolic pathways
  • Figure 3.18: Technologies used in proteomics
  • Figure 3.19: 1H NMR spectrum of urine showing functional windows
  • Figure 3.20: Large scale metabolomic screening of human populations: identifying outliers
  • Figure 4.21: Standardized qualifying language for qualified health claims
  • Figure 4.22: Examples of structure/function claims allowed on food labeling
  • Figure 5.23: Recent products launched that contain TEAVIGO??
  • Figure 5.24: Development of new probiotic cultures at Chr. Hansen
  • Figure 5.25: Nestl's products by functional category, 2004-2006
  • Figure 5.26: Nestl's functional brands (2005)
  • Figure 5.27: Nestle NesVita Pro-Heart Probiotic Drink
  • Figure 5.28: Unilever's products by functional category, 2004-2006
  • Figure 5.29: Flora Pro-Active Blood Pressure Mini Drink
  • Figure 5.30: Ajinomoto products by functional category, 2004-2006
  • Figure 5.31: Calpis Ameal S Maiasa Yasai (vegetable breakfast drink)
  • Figure 5.32: Danone's products by functional category, 2004-2006
  • Figure 5.33: Danone Petit Danone Cheese Dessert
  • Figure 5.34: Coca-Cola's products by functional category, 2004-2006
  • Figure 5.35: Enviga
  • Figure 5.36: Novartis' Benefiber Clear Choice! Powder and Isocal Jelly Arg Jelly Dessert
  • Figure 6.37: Awareness and favorability towards personalized nutrition
• List of Tables
  • Table 1.1: Number and percentage of overweight and obese adults by country, 2005-2010 (% adult population)
  • Table 1.2: Size of the diet food and drinks market and the obesity pharmaceutical market, (US$,m), 2005-2010
  • Table 1.3: Estimated prevalence of major cardiovascular diseases in the seven major markets, 2004
  • Table 1.4: Size of the food and drinks and pharmaceutical markets for heart health, (US$,m), 2005-2010
  • Table 1.5: Prevalence of type-2 diabetes in the 7 major markets, 2005-11
  • Table 1.6: Size of the pharmaceutical market for diabetes, (US$,m), 2005-2010
  • Table 1.7: Prevalence of Rheumatoid Arthritis based on population > 60 in the seven major markets (000s), 2005–2010
  • Table 1.8: Prevalence of osteoporosis in men and women over 50 across the seven major markets, 2005
  • Table 1.9: Size of the food and drinks and pharmaceutical markets for bone health, (US$m), 2005-2010
  • Table 2.10: Functional ingredients
  • Table 2.11: Functional food ingredients (cont.)
  • Table 2.12: Examples of functional food ingredients and the scientific basis for health benefit claims
  • Table 2.13: Functional food and drink sales by value ($m), 2005-2008
  • Table 3.14: Companies offering nutrigenetic testing and dietary advice, 2006
  • Table 3.15: Genetic variations screened by the Cellf??Assessment Kit from Sciona, 2006
  • Table 3.16: How nutrients alter gene expression
  • Table 3.17: Examples of transcriptomics in nutritional biology and nutrigenomics
  • Table 3.18: Companies and research centres utilizing gene expression analysis for nutrigenomic applications
  • Table 4.19: FOSHU functions and functional food components
  • Table 4.20: Generic health claims currently approved by the FDA
  • Table 4.21: Regulatory opportunities and threats in the functional foods industry
  • Table 5.22: Ajinomoto products containing AmealPeptide??launched in Japan
  • Table 5.23: Recent functional food and drinks launches
  • Table 5.24: Some functional food and drink products launched by pharma companies
  • Table 5.25: Consortia involved in the International Nutrigenomics Network
  • Table 5.26: Examples of other collaborative nutrigenomic research projects
  • Table 6.27: Biomarkers for well-being and disease risk reduction